50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
CEO of biggest PE firm predicts “social unrest” (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
CEO of biggest PE firm predicts “social unrest” (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
CEO of biggest PE firm predicts “social unrest” (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
CEO of biggest PE firm predicts “social unrest” (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
OTCMKTS:UCBJF

UCB - UCBJF Stock Forecast, Price & News

$73.25
0.00 (0.00%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$73.25
$73.25
50-Day Range
$68.96
$85.60
52-Week Range
$68.96
$122.90
Volume
N/A
Average Volume
479 shs
Market Capitalization
$13.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$101.71

UCB MarketRank™ Forecast

Analyst Rating
Hold
2.11 Rating Score
Upside/​Downside
38.9% Upside
$101.71 Price Target
Short Interest
Healthy
0.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of UCB in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.99%
From $4.14 to $5.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

UCBJF stock logo

About UCB (OTCMKTS:UCBJF) Stock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Stock News Headlines

UCB (OTCMKTS:UCBJF) Upgraded by Jefferies Financial Group to "Buy"
Short Interest in UCB SA (OTCMKTS:UCBJF) Drops By 17.5%
UCB (OTCMKTS:UCBJF) Lifted to "Neutral" at Citigroup
UCB (OTCMKTS:UCBJF) Lowered to "Underperform" at Credit Suisse Group
UCB (OTCMKTS:UCBJF) Sets New 52-Week Low at $68.96
ZGNX Jan 2022 7.000 call
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Why New Oriental Education Shares Are Falling
SpectrumDNA, Inc. (SPXA)
UCB unleashes the power of data in new collaboration
See More Headlines
Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Company Calendar

Today
9/24/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:UCBJF
Employees
8,561
Year Founded
1928

Price Target and Rating

Average Stock Price Forecast
$101.71
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$86.00
Forecasted Upside/Downside
+38.9%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
9 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.84 billion
Cash Flow
$7.67 per share
Book Value
$52.49 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.85 billion
Optionable
Not Optionable
Beta
0.63

Social Links


Key Executives

  • Mr. Jean-Christophe Tellier (Age 63)
    CEO & Exec. Director
    Comp: $4.37M
  • Ms. Sandrine Dufour CFA (Age 56)
    Exec. VP & CFO
  • Ms. Kirsten Lund-Jurgensen (Age 63)
    Exec. VP of Supply & Technology Solutions
  • Dr. Dhavalkumar D. Patel M.D. (Age 61)
    Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. William J. Silbey (Age 63)
    Exec. VP & Gen. Counsel
  • Mr. Jean-Luc Fleurial (Age 57)
    Exec. VP & Chief HR Officer
  • Prof. Iris Low-Friedrich (Age 62)
    Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices
  • Mr. Emmanuel Caeymaex (Age 53)
    Exec. VP of Immunology Solutions & Head of US
  • Mr. Charl van Zyl (Age 55)
    Exec. VP of Neurology Solutions & Head of EU/International
  • Ms. Caroline Vancoillie
    Chief Accounting Officer & CFO of Patient Value Functions













UCBJF Stock - Frequently Asked Questions

Should I buy or sell UCB stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" UCBJF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UCBJF, but not buy additional shares or sell existing shares.
View UCBJF analyst ratings
or view top-rated stocks.

What is UCB's stock price forecast for 2022?

9 equities research analysts have issued 1 year target prices for UCB's stock. Their UCBJF share price forecasts range from $86.00 to $120.00. On average, they predict the company's stock price to reach $101.71 in the next year. This suggests a possible upside of 38.9% from the stock's current price.
View analysts price targets for UCBJF
or view top-rated stocks among Wall Street analysts.

How have UCBJF shares performed in 2022?

UCB's stock was trading at $107.96 on January 1st, 2022. Since then, UCBJF shares have decreased by 32.2% and is now trading at $73.25.
View the best growth stocks for 2022 here
.

Are investors shorting UCB?

UCB saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 551,900 shares, a decline of 17.5% from the August 15th total of 668,800 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is presently 1,839.7 days.
View UCB's Short Interest
.

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $73.25.

How much money does UCB make?

UCB (OTCMKTS:UCBJF) has a market capitalization of $13.85 billion and generates $6.84 billion in revenue each year.

How many employees does UCB have?

The company employs 8,561 workers across the globe.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The official website for the company is www.ucb.com. The company can be reached via phone at (322) 559-9999, via email at investor-relations@ucb.com, or via fax at 32-2559-9900.

This page (OTCMKTS:UCBJF) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.